HFE Protein - Homeostatic Iron Regulator

HFE Protein - Homeostatic Iron Regulator

Introduction

The HFE protein (Homeostatic Iron Regulator) is a membrane protein that plays a critical role in systemic iron metabolism. Mutations cause hereditary hemochromatosis and are associated with increased risk of neurodegenerative diseases due to iron accumulation in the brain.

<div class="infobox infobox-protein">
<h3>HFE Protein</h3>
<table>
<tr><th>Protein Name</th><td>Homeostatic Iron Regulator (HFE)</td></tr>
<tr><th>Gene</th><td>[HFE](/genes/hfe)</td></tr>
<tr><th>UniProt ID</th><td>[Q30201](https://www.uniprot.org/uniprot/Q30201)</td></tr>
<tr><th>Molecular Weight</th><td>~40 kDa</td></tr>
<tr><th>Subcellular Localization</th><td>Cell membrane, Endoplasmic reticulum</td></tr>
<tr><th>Protein Family</th><td>MHC class I family</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ischemia" style="color:#ef9a9a">Ischemia</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">19 edges</a></td>
</tr>
</table>
</div>

Overview

HFE Protein - Homeostatic Iron Regulator

Introduction

The HFE protein (Homeostatic Iron Regulator) is a membrane protein that plays a critical role in systemic iron metabolism. Mutations cause hereditary hemochromatosis and are associated with increased risk of neurodegenerative diseases due to iron accumulation in the brain.

<div class="infobox infobox-protein">
<h3>HFE Protein</h3>
<table>
<tr><th>Protein Name</th><td>Homeostatic Iron Regulator (HFE)</td></tr>
<tr><th>Gene</th><td>[HFE](/genes/hfe)</td></tr>
<tr><th>UniProt ID</th><td>[Q30201](https://www.uniprot.org/uniprot/Q30201)</td></tr>
<tr><th>Molecular Weight</th><td>~40 kDa</td></tr>
<tr><th>Subcellular Localization</th><td>Cell membrane, Endoplasmic reticulum</td></tr>
<tr><th>Protein Family</th><td>MHC class I family</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ischemia" style="color:#ef9a9a">Ischemia</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">19 edges</a></td>
</tr>
</table>
</div>

Overview

The HFE protein (Homeostatic Iron Regulator) is a 348-amino acid transmembrane protein that functions as a key regulator of iron homeostasis in the body[@references]. Initially discovered as the protein defective in hereditary hemochromatosis, HFE has since been implicated in neurodegenerative diseases through its effects on brain iron metabolism[@ref1996]. The protein is structurally related to major histocompatibility complex (MHC) class I molecules but does not present antigens; instead, it functions in iron sensing and regulation[@ref2011].

Structure

Domain Architecture

| Domain | Description | Function |
|--------|-------------|----------|
| Alpha-1 domain | N-terminal extracellular | Protein-protein interactions |
| Alpha-2 domain | Extracellular | Ligand binding |
| Alpha-3 domain | Extracellular | Binds beta-2-microglobulin |
| Transmembrane domain | Single helix | Membrane anchoring |
| Cytoplasmic tail | Intracellular | Intracellular signaling |

Key Structural Features

• MHC-like fold: HFE shares the characteristic MHC class I three-domain structure.
• Beta-2-microglobulin binding: Required for proper folding and cell surface expression.
• Transferrin receptor interaction site: The alpha-1 and alpha-2 domains mediate binding to TfR1.
• Cysteine residues: Form disulfide bonds important for structural stability.

Post-Translational Modifications

• N-linked glycosylation: Multiple sites for carbohydrate attachment.
• Palmitoylation: May affect membrane localization.
• Phosphorylation: Potential regulatory sites.

Normal Function

Iron Regulation

• Iron sensing: HFE monitors body iron status through interaction with transferrin receptor 1 (TfR1) on cell surfaces.
• Hepcidin regulation: HFE is essential for appropriate hepcidin expression in response to body iron levels.
• Intestinal absorption: By controlling hepcidin, HFE regulates dietary iron uptake in the duodenum.
• Cellular iron uptake: Modulates transferrin-mediated iron uptake via TfR1.

Tissue Distribution

• High expression: Liver, small intestine (duodenum), spleen, heart.
• Moderate expression: Brain ([neurons](/entities/neurons), [microglia](/cell-types/microglia-neuroinflammation), endothelial cells).
• Cellular localization: Primarily plasma membrane and endoplasmic reticulum.

Role in Disease

Hereditary Hemochromatosis

Mutations in HFE cause the most common form of hereditary hemochromatosis (type 1):

• C282Y mutation: Most common pathogenic variant; disrupts disulfide bond, prevents proper folding.
• H63D mutation: Mild functional impairment; incomplete penetrance.
• S65C mutation: Rare; mild functional effect.

Neurodegeneration

Alzheimer's Disease

• Iron accumulation: Elevated iron in AD brain regions ([hippocampus](/brain-regions/hippocampus), basal ganglia).
• Mechanisms: Iron promotes [amyloid-beta](/proteins/amyloid-beta) aggregation, oxidative stress, neuronal death.
• Evidence: HFE variants associated with increased AD risk in some populations[@ref2010].

Parkinson's Disease

• Substantia nigra: Iron accumulation is a hallmark of PD pathology.
• Dopaminergic neurons: Particularly vulnerable to iron-induced oxidative damage.
• HFE variants: May modify PD onset age and severity[@ref2023].

Other Neurodegenerative Conditions

• Amyotrophic Lateral Sclerosis: Iron dysregulation in motor neurons.
• Multiple System Atrophy: Iron accumulation in putamen and cerebellum.
• NBIA: Iron accumulation disorders.

Mechanisms of Neurotoxicity

Therapeutic Targeting

Iron Chelation Therapy

| Drug | Route | [BBB](/entities/blood-brain-barrier) Penetration | Clinical Use |
|------|-------|------------------|--------------|
| Deferoxamine | IV/SC | Limited | FDA approved |
| Deferasirox | Oral | Moderate | FDA approved |
| Deferiprone | Oral | Good | Trials for PD/AD |

Emerging Approaches

• HFE gene therapy: AAV-mediated delivery.
• Hepcidin modulators: Therapeutic targeting of the HFE-hepcidin pathway.
• Antioxidants: Neuroprotective strategies.
• Ferroptosis inhibitors: Liproxstatin-1, ferrostatin-1.

Animal Models

• Hfe knockout mice: Spontaneous iron accumulation; useful for studying iron's role in neurodegeneration.
• Hfe/APP double transgenic: Synergistic effects on amyloid pathology and oxidative stress.
• Hfe/alpha-synuclein models: Investigate iron in synucleinopathies.

Key Publications

See Also

• [/genes/hfe](/genes/hfe)
• [/diseases/hereditary-hemochromatosis](/diseases/hereditary-hemochromatosis)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [/mechanisms/iron-metabolism-neurodegeneration](/mechanisms/iron-metabolism-neurodegeneration)
• [/mechanisms/oxidative-stress-neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)

External Links

• [UniProt: Q30201](https://www.uniprot.org/uniprot/Q30201)
• [NCBI Gene: HFE](https://www.ncbi.nlm.nih.gov/gene/3077)
• [OMIM: 235200](https://www.omim.org/entry/235200)
• [Iron Disorders Institute](https://www.irondisorders.org/)

References